SanFran,

Sorry to burst your bubble, but the ADA 2017 abstract entitled "Apabetalone (RVX-208) Lowers Major Adverse Cardiovascular Events (MACE) in CVD Patients with Diabetes Mellitus by Affecting Complement Pathway and Microbiome Activity" is very similar in content to abstracts presented earlier this year at ACC and EAS, as well as last year at EASD. Seems to be the same story, different conference. So after ADA 2017, they will have presented this similar story at cardiology (EAS, ACC) and diabetes (EASD, ADA) conferences in both Europe and USA.

I'm not trying to take away from the importance and medical relevance of these findings, just pointing out the redundancy in the presentation of this data over the past 9 months. 

EASD 2016 "Apabetalone (RVX-208) acts on epigenetics to lower Major Adverse Cardiovascular Events (MACE) in diabetes mellitus patients with atherosclerosis via microbiome activity." Here is a link to the abstract and here is a link to the poster that was presented on September 14, 2016. Additionally, Resverlogix has a blog about this presentation and in the blog is a link to Dr. Wong narrating his poster.

ACC 2017 "Apabetalone (RVX-208) Lowers Cardiovascular Disease (CVD) In Diabetes Mellitus by a Mechanism Involving Microbiome Mediated Activity on the Complement Pathway." Here is a link to the abstract and here is a link to the poster that was presented on March 17, 2017.

EAS 2017 "Apabetalone (RVX-208) May Lower CVD Events in Diabetes Mellitus by Affecting Complement Pathway and Microbiome Activity." This poster was presented on April 24, 2017 but neither the conference website or Resverlogix website has the abstract or poster available.